Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
Summary
- Eligibility
- for people ages 1-11 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Regeneron Pharmaceuticals
- ID
- NCT04394351
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated